Welcome to our dedicated page for IMMUTEP SEC filings (Ticker: IMMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IMMUTEP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IMMUTEP's regulatory disclosures and financial reporting.
Immutep Limited furnishes a Form 6-K that includes an exhibit titled “Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study.” This indicates the company is providing investors with a positive clinical update on IMP761, which it describes as a first-in-class LAG-3 agonist antibody being studied for autoimmune diseases in a Phase I trial. The detailed results and implications of this Phase I study are contained in the attached exhibit, which is referenced but not reproduced here.
Immutep Limited submitted a Form 6-K to provide investors with an accompanying report on its clinical development activities. The filing mainly serves as a cover document for an exhibit rather than a detailed operational or financial update.
The attached exhibit, titled “Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace,” signals that the company is highlighting progress and ongoing patient enrolment in its global TACTI-004 (KEYNOTE-F91) Phase III trial.
Immutep Limited, an Australia-based biotechnology company, has filed a report indicating it will present new data from its AIPAC-003 Phase II study at the 2025 San Antonio Breast Cancer Symposium. This presentation highlights ongoing clinical development work in breast cancer and suggests continued progress in evaluating its experimental therapy in this indication.
Immutep Limited furnished a Form 6-K that attaches an exhibit summarizing translational data and significant pathologic response rates from its EFTISARC-NEO Phase II study. These results were highlighted in an oral presentation at the CTOS 2025 conference, and the filing formally submits that presentation information to U.S. investors.
Immutep Limited furnished a Form 6-K noting it received an A$4.6 million research and development tax incentive from the French Government. This inflow reflects government support tied to the company’s R&D activities.
The update is administrative in nature but adds cash to the business, as disclosed in the exhibit titled “Immutep Receives A$4.6 million R&D Tax Incentive from French Government.”
Immutep Limited filed its annual report on Form 20-F, outlining ongoing development of LAG‑3 immunotherapies and continued operating losses. The company reported a net loss of A$61.4 million for the fiscal year ended June 30, 2025, compared with A$42.7 million in 2024. Shares outstanding were 1,460,389,575 as of June 30, 2025. Its ADSs, each representing 10 ordinary shares, trade on Nasdaq as IMMP.
Immutep has no products approved for sale and is focused on clinical candidates including eftilagimod alfa (efti), IMP761, and partnered programs such as IMP701 (ieramilimab) with Novartis. The company has collaboration and supply agreements with Merck & Co. for pembrolizumab combination trials (Phase II and Phase III) and with Merck KGaA/Pfizer for avelumab (Phase I), and a regional license with EOC Pharma in China.
Management expects further losses as clinical activities expand and notes reliance on third‑party manufacturers, trial enrollment challenges, regulatory risks, and the need for additional financing. Financial statements are prepared under IFRS and presented in Australian dollars.
Immutep Limited filed a Form 6-K to furnish information about scientific presentations at a major oncology meeting. The filing notes an exhibit titled “Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer.”
Immutep Limited furnished a Form 6-K noting that the EFTISARC-NEO Phase II trial evaluating neoadjuvant efti in soft tissue sarcoma met its primary endpoint, with data presented at the ESMO Congress 2025.
The update is provided via Exhibit 99.1. Additional clinical details would be contained in the exhibit presentation materials.
Immutep Limited furnished a Form 6-K reporting an exhibit titled “Immutep Announces Successful Completion of FDA Project Optimus Requirements.” The notice identifies Exhibit 99.1 as the related material and is dated October 13, 2025.